Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 2, 2014, Pages 171-177

  Delchier, J C ^a   Malfertheiner, P ^b   Thieroff Ekerdt, R ^c  

^a HENRI MONDOR HOSPITAL   (France)

^b Klinic fur Gastroenterologie Hepatologie and Infektiologie   (Germany)

^c Aptalis Pharma US   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH CITRATE; CLARITHROMYCIN; HELIDAC; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE; UREA C 13;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACKACHE; BREATH ANALYSIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; VOMITING; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BREATH TESTS; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; TETRACYCLINE; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84902824654     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12808     Document Type: Article

References (27)

1. Hunt RH, Xiao SD, Megraud F, et al,.; World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointest Liver Dis 2011; 20: 299-304.
2. Schöttker B, Adamu MA, Weck MN, Brenner H,. Helicobacter pylori infection is strongly associated with gastric and duodenal ulcers in a large prospective study. Clin Gastroenterol Hepatol 2012; 10: 487-93.
3. Malfertheiner P, Megraud F, O'Morain CA, et al,.; European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
4. Megraud F, Coenen S, Versporten A, et al. Study Group Participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
5. Selgrad M, Meissle J, Bornschein J, et al,. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol 2013; 25: 1257-60.
6. Zullo A, De Francesco V, Hassan C,. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks!. J Clin Gastroenterol 2012; 46: 259-61.
7. Giorgio F, Principi M, De Francesco V, et al,. Primary clarithromycin resistance to Helicobacter pylori: is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol 2013; 4: 43-6.
8. Graham DY, Fischbach L,. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
9. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J,. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-7.
10. Malfertheiner P, Bazzoli F, Delchier JC, et al,.; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.
11. Chey WD, Wong BC,; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
12. Fock KM, Katelaris P, Sugano K, et al,. Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-600.
13. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD,. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
14. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P,. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88: 33-45.
15. Tillman LA, Drake FM, Dixon JS, Wood JR,. Review article: safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol Ther 1996; 10: 459-67.
16. Serfontein WJ, Mekel R,. Bismuth toxicity in man II. Review of bismuth blood and urine levels in patients after administration of therapeutic bismuth formulations in relation to the problem of bismuth toxicity in man. Res Commun Chem Pathol Pharmacol 1979; 26: 391-411.
17. Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M,. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. J Clin Pharmacol 2004; 44: 640-5.
18. Marshall BJ,. The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology. Am J Gastroenterol 1991; 86: 16-25.
19. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P,. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361-70.
20. Fischbach L, Evans EL,. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-57.
21. Wu W, Yang Y, Sun G,. Recent insights into antibiotic resistance in Helicobacter pylori eradication. Gastroenterol Res Pract 2012; 2012: 723183.
22. Kim MS, Kim N, Kim SE, et al,. Long-term follow up Helicobacter pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC Gastroenterol 2013; 13: 138.
23. Wang Z, Wu S,. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J 2012; 53: 273-6.
24. Lee BH, Kim N, Hwang TJ, et al,. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45.
25. Gisbert JP, Perez-Aisa A, Rodrigo L, et al,.; H. pylori Study Group of the Spanish Gastroenterology Association. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. Dig Dis Sci 2014; 59: 383-9.
26. Salazar CO, Cardenas VM, Reddy RK, Dominguez DC, Snyder LK, Graham DY,. Greater than 95% success with 14-day bismuth quadruple anti-Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter 2012; 17: 382-90.
27. Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY,. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011; 16: 295-300.